ClinConnect ClinConnect Logo
Search / Trial NCT06696534

Exploring Participant Preference for Screening Methods and Experience Into Colorectal Cancer Screening Programme

Launched by ADVANCED MARKER DISCOVERY S.L. · Nov 16, 2024

Trial Information

Current as of November 14, 2025

Not yet recruiting

Keywords

Colorectal Cancer Screening Programme Experience Preference Questionnaire

ClinConnect Summary

This clinical trial is looking at how people feel about different ways to screen for colorectal cancer, which is cancer of the colon or rectum. The study aims to understand what screening methods people prefer and how they feel about their experiences with these tests, specifically after taking a stool test called FOBT (Fecal Occult Blood Test). The trial will involve participants aged 50 to 69 years who are healthy and eligible for screening. They will complete two questionnaires to share their thoughts and experiences, and their responses will help improve future screening programs.

To participate, individuals need to be between 50 and 69 years old and be invited to join a screening program at a health center. They must also be willing to sign a consent form, confirming they understand what the study involves. However, individuals who have already had a colonoscopy because of a previous positive stool test, or who haven’t submitted a stool sample yet, won’t be eligible. This study is important because it aims to make colorectal cancer screening more patient-friendly by taking into account what people prefer and how they feel about the process.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Participants ages from 50 to 69 years (both included) at the time of informed consent signed.
  • Participants invited to participate in population-based screening programme who are eligible to undertake FOBT at the Primary Health Care Center.
  • Participants should sign an informed consent. They must understand the nature, significance, implications, and risks of the clinical study before signing the informed consent form.
  • Exclusion Criteria:
  • Participants who have not delivery a stool sample in the Primary Health Care Center before signing the informed consent form.
  • Participants with a previous colonoscopy in consequence of a FOBT positive result.
  • Participants who are in a dependent personal or non-medical relationship with the Sponsor or the Investigators.

About Advanced Marker Discovery S.L.

Advanced Marker Discovery S.L. is a leading biotechnology company focused on the development and commercialization of innovative diagnostic solutions and therapeutic biomarkers. With a commitment to advancing precision medicine, the company leverages cutting-edge technologies and extensive research to identify and validate novel biomarkers that enhance disease detection, monitoring, and treatment efficacy. Through strategic collaborations and robust clinical trial sponsorship, Advanced Marker Discovery aims to transform patient care by providing healthcare professionals with actionable insights and tools to improve clinical outcomes.

Locations

Lisbon, Portugal

Madrid, Spain

Patients applied

0 patients applied

Trial Officials

Maria A Perez, MD

Principal Investigator

Primary Health Care Centre Mar Báltico

Ana Rita, MD

Principal Investigator

Unidade Local de Saúde de Santa Maria

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported